58-37-112. Labeling and packaging controlled substance -- Informational pamphlet for opiates -- Naloxone education and offer to dispense.

533 words·~2 min read·/ut/title-58/chapter-37/58-37-112·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

Effective 5/6/2026

(1)A person licensed under this chapter may not distribute a controlled substance unless the controlled substance is packaged and labeled in compliance with the requirements of Section 305 of the federal Comprehensive Drug Abuse Prevention and Control Act of 1970.

(2)No person, except a pharmacist for the purpose of filling a prescription, may alter, deface, or remove any label affixed by the manufacturer.

(3)Whenever a pharmacy sells or dispenses any controlled substance on a prescription issued by a practitioner, the pharmacy shall affix to the container in which the substance is sold or dispensed:

(a)a label showing the:

(i)pharmacy name and address;

(ii)serial number; and

(iii)date of initial filling;

(b)the prescription number, the name of the patient, or if the patient is an animal, the name of the owner of the animal and the species of the animal;

(c)the name of the practitioner by whom the prescription was written;

(d)any directions stated on the prescription; and

(e)any directions required by rules and regulations promulgated by the department.

(4)Whenever a pharmacy sells or dispenses a Schedule II or Schedule III controlled substance that is an opiate, the pharmacy shall:

(a)affix a warning to the container or the lid for the container in which the substance is sold or dispensed that contains the following text:

(i)"Caution: Opioid. Risk of overdose and addiction"; or

(ii)any other language that is approved by the Department of Health and Human Services;

(b)beginning January 1, 2024:

(i)offer to counsel the patient or the patient's representative on the use and availability of an opiate antagonist as defined in Section 26B-4-501 ; and

(ii)offer to dispense an opiate antagonist as defined in Section 26B-4-501 to the patient or the patient's representative, under a prescription from a practitioner or under Section 26B-4-510 , if the patient:

(A)receives a single prescription for 50 morphine milligram equivalents or more per day, calculated in accordance with guidelines developed by the United States Centers for Disease Control and Prevention;

(B)is being dispensed an opioid and the pharmacy dispensed a benzodiazepine to the patient in the previous 30-day period; or

(C)is being dispensed a benzodiazepine and the pharmacy dispensed an opioid to the patient in the previous 30-day period.

(a)A pharmacy who sells or dispenses a Schedule II or Schedule III controlled substance that is an opiate shall, if available from the Department of Health and Human Services, prominently display at the point of sale the informational pamphlet developed by the Department of Health and Human Services under Section 26B-4-514 .

(b)The board and the Department of Health and Human Services shall encourage pharmacies to use the informational pamphlet to engage in patient counseling regarding the risks associated with taking opiates.

(c)The requirement in Subsection (5)(a) does not apply to a pharmacy if the pharmacy is unable to obtain the informational pamphlet from the Department of Health and Human Services for any reason.

Renumbered and Amended by Chapter 362 , 2026 General Session